# Advocates Call for Wider Access to Medical Cannabis in Women’s Health Conditions > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/advocates-call-for-wider-access-to-medical-cannabis-in-womens-health-conditions/ > **Published:** 2026-05-20T23:59:35-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:54:39-04:00 > **Clinical Summary:** Cannabis PTSD women evidence remains limited. Learn what clinical trials show and how to counsel patients on trauma-focused therapies. --- ✦ New CED Clinical Relevance #76 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. Mental HealthResearchPolicyAnxietyPTSDWomen’s HealthSafety Why This Matters Clinicians treating women with trauma-related conditions like PTSD and sexual trauma need current evidence on cannabis efficacy and safety to counsel patients accurately, as advocacy for expanded access may outpace clinical data on effectiveness and potential risks in this population. Understanding the regulatory landscape around medical cannabis in women’s health allows providers to discuss evidence-based alternatives, potential benefits, and documented harms when patients inquire about or request cannabis treatment. This gap between patient interest and clinical evidence underscores the need for robust research trials to establish whether cannabis offers genuine therapeutic advantage over existing treatments for these conditions. Clinical Summary Advocates are calling for expanded access to medical cannabis to treat women-specific health conditions, particularly focusing on trauma-related disorders such as PTSD and sequelae of sexual trauma, based on emerging observational research suggesting potential therapeutic benefits in these populations. Currently, limited clinical evidence and regulatory restrictions constrain prescribing options for women presenting with these complex conditions, despite preliminary data suggesting cannabis may offer symptom relief when conventional treatments are insufficient or poorly tolerated. The push for wider access reflects a gap between patient interest and clinical evidence, highlighting the need for rigorous [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) in women’s health populations that have historically been underrepresented in [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/). Clinicians should be aware that many female patients with trauma histories are already self-medicating with cannabis and that controlled research is urgently needed to establish efficacy, optimal dosing, and safety profiles in these vulnerable populations. Given the high burden of PTSD and trauma-related disorders in women, physicians may encounter growing patient interest in cannabis as adjunctive therapy and should stay informed about evolving evidence as well as local regulatory frameworks. Clinicians should counsel patients about current evidence limitations while advocating for the research infrastructure and regulatory pathways necessary to rigorously evaluate cannabis for women’s trauma-related conditions. Dr. Caplan’s Take “The evidence for cannabis in treating trauma-related conditions in women is compelling enough that we’re doing a disservice by maintaining blanket restrictions, yet we still lack the rigorous [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) that would let us prescribe with the same confidence we have for other conditions, and that gap between clinical observation and regulatory permission is where many of my patients suffer unnecessarily.” Clinical Perspective While advocacy for [medical cannabis access](https://cedclinic.com/medical-marijuana-card-reciprocity/) in women’s health—particularly for trauma-related conditions like PTSD—reflects genuine patient interest and emerging preclinical rationale, clinicians should recognize that robust clinical trial evidence remains limited in this population. The existing literature on cannabis for PTSD and trauma-related symptoms comes primarily from small studies, observational reports, or research in predominantly male veteran populations, making direct extrapolation to women uncertain. Important confounders include variability in cannabis potency and composition, individual differences in [cannabinoid metabolism](https://cedclinic.com/fatty-acid-amide-hydrolase-obesity-risk-genetic-links/), potential interactions with psychotropic medications commonly used in trauma treatment, and the risk of symptom substitution or dependence in vulnerable populations. Rather than waiting for access policies to outpace evidence, clinicians can engage interested patients in shared decision-making that acknowledges both the theoretical rationale and knowledge gaps, documents baseline symptom severity and function, and maintains parallel engagement with evidence-based trauma therapies while any 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/mental-health/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Advocates%20Call%20for%20Wider%20Access%20to%20Medical%20Cannabis%20in%20Women%27s%20Health%20Conditions%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D55849)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D55849)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Advocates%20Call%20for%20Wider%20Access%20to%20Medical%20Cannabis%20in%20Women%27s%20Health%20Conditions%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D55849)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) 📰 Source: [https://cannabishealthnews.co.uk/2026/05/20/advocates-call-for-wider-access-to-medical-cannabis-in-womens-health-conditions/](https://cannabishealthnews.co.uk/2026/05/20/advocates-call-for-wider-access-to-medical-cannabis-in-womens-health-conditions/) Further Reading Cannabis Policy Wire[Schedules of Controlled Substances: Placement of MDMB-4en-PINACA in Schedule I](https://cedclinic.com/mdmb-4en-pinaca-schedule-i-placement/) Cannabis Policy Wire[The Use of Cannabidiol Suppositories for Sexual Pain](https://cedclinic.com/cannabidiol-suppositories-sexual-pain-treatment-clinical-trial/) CED Clinic Blog[Fear of recurrence, secondary cancers, and health problems in long-term survivors of childhood cancer: Findings from a Canadian cohort.](https://cedclinic.com/fear-of-recurrence-secondary-cancers-and-health-problems-in-long-term-survi/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).